US Patent

US7659282 — Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders

Method of Use · Assigned to Avanir Pharmaceuticals Inc · Expires 2026-08-13 · 0y remaining

Vulnerability score 85/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects pharmaceutical compositions that combine dextromethorphan and quinidine for treating neurological disorders.

USPTO Abstract

Pharmaceutical compositions and methods for treating neurological disorders by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine.

Drugs covered by this patent

dextromethorphan-hydrobromide (DEXTROMETHORPHAN HYDROBROMIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1093`	—	dextromethorphan-hydrobromide

Patent Metadata

Patent number: US7659282
Jurisdiction: US
Classification: Method of Use
Expires: 2026-08-13
Drug substance claim: No
Drug product claim: No
Assignee: Avanir Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.